139 related articles for article (PubMed ID: 20015005)
1. Anti-cancer approach with NK4: Bivalent action and mechanisms.
Nakamura T; Sakai K; Nakamura T; Matsumoto K
Anticancer Agents Med Chem; 2010 Jan; 10(1):36-46. PubMed ID: 20015005
[TBL] [Abstract][Full Text] [Related]
2. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
3. Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association.
Sakai K; Nakamura T; Matsumoto K; Nakamura T
J Biol Chem; 2009 Aug; 284(33):22491-22499. PubMed ID: 19553700
[TBL] [Abstract][Full Text] [Related]
4. NK4 gene therapy targeting HGF-Met and angiogenesis.
Matsumoto K; Nakamura T
Front Biosci; 2008 Jan; 13():1943-51. PubMed ID: 17981681
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms and significance of bifunctional NK4 in cancer treatment.
Matsumoto K; Nakamura T
Biochem Biophys Res Commun; 2005 Jul; 333(2):316-27. PubMed ID: 15950947
[TBL] [Abstract][Full Text] [Related]
6. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics.
Matsumoto K; Nakamura T
Cancer Sci; 2003 Apr; 94(4):321-7. PubMed ID: 12824898
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model.
Tomioka D; Maehara N; Kuba K; Mizumoto K; Tanaka M; Matsumoto K; Nakamura T
Cancer Res; 2001 Oct; 61(20):7518-24. PubMed ID: 11606388
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.
Suzuki Y; Sakai K; Ueki J; Xu Q; Nakamura T; Shimada H; Nakamura T; Matsumoto K
Int J Cancer; 2010 Oct; 127(8):1948-57. PubMed ID: 20104519
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
Matsumoto K; Nakamura T; Sakai K; Nakamura T
Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
[TBL] [Abstract][Full Text] [Related]
10. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells.
Kuba K; Matsumoto K; Ohnishi K; Shiratsuchi T; Tanaka M; Nakamura T
Biochem Biophys Res Commun; 2000 Dec; 279(3):846-52. PubMed ID: 11162438
[TBL] [Abstract][Full Text] [Related]
11. HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics.
Mizuno S; Nakamura T
Int J Mol Sci; 2013 Jan; 14(1):888-919. PubMed ID: 23296269
[TBL] [Abstract][Full Text] [Related]
12. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice.
Wen J; Matsumoto K; Taniura N; Tomioka D; Nakamura T
Cancer Gene Ther; 2004 Jun; 11(6):419-30. PubMed ID: 15017381
[TBL] [Abstract][Full Text] [Related]
13. Cooperative interaction between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses.
Matsumoto K; Kataoka H; Date K; Nakamura T
J Biol Chem; 1998 Sep; 273(36):22913-20. PubMed ID: 9722511
[TBL] [Abstract][Full Text] [Related]
14. Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells.
Parr C; Hiscox S; Nakamura T; Matsumoto K; Jiang WG
Int J Cancer; 2000 Feb; 85(4):563-70. PubMed ID: 10699931
[TBL] [Abstract][Full Text] [Related]
15. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y
Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor.
Date K; Matsumoto K; Kuba K; Shimura H; Tanaka M; Nakamura T
Oncogene; 1998 Dec; 17(23):3045-54. PubMed ID: 9881707
[TBL] [Abstract][Full Text] [Related]
17. Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy.
Maemondo M; Narumi K; Saijo Y; Usui K; Tahara M; Tazawa R; Hagiwara K; Matsumoto K; Nakamura T; Nukiwa T
Mol Ther; 2002 Feb; 5(2):177-85. PubMed ID: 11829525
[TBL] [Abstract][Full Text] [Related]
18. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells.
Jiang WG; Hiscox SE; Parr C; Martin TA; Matsumoto K; Nakamura T; Mansel RE
Clin Cancer Res; 1999 Nov; 5(11):3695-703. PubMed ID: 10589789
[TBL] [Abstract][Full Text] [Related]
19. NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells.
Maehara N; Matsumoto K; Kuba K; Mizumoto K; Tanaka M; Nakamura T
Br J Cancer; 2001 Mar; 84(6):864-73. PubMed ID: 11259105
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice.
Ueda K; Iwahashi M; Matsuura I; Nakamori M; Nakamura M; Ojima T; Naka T; Ishida K; Matsumoto K; Nakamura T; Yamaue H
Eur J Cancer; 2004 Sep; 40(14):2135-42. PubMed ID: 15341989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
